Navigation Links
Cytopia Merger with Toronto-based YM BioSciences Inc.
Date:10/5/2009

al being announced.
  • Each of Cytopia and YM has agreed to the payment of a break fee of A$500,000 under certain circumstances.
  • For the period commencing on the date of the Agreement until the earlier of termination of the Agreement or 28 February 2010, Cytopia has agreed not to solicit, encourage, initiate or participate in any negotiations or discussions in respect of an expression of interest, offer or proposal for an alternative transaction to the Scheme(s) (subject to the fiduciary duties of Cytopia's directors).
  • On successful implementation of the Scheme(s), Cytopia will be delisted from ASX.
  • Full details of the merger will be provided to Cytopia shareholders and optionholders in a Scheme Booklet which is expected to be distributed in late November 2009. The Scheme Booklet will include the report from the independent expert and will further explain the basis for the proposed merger.

    It is expected that shareholders, and optionholders if necessary, will be asked to vote on the approval of the Scheme(s) in January 2010.

    Cytopia has appointed Clayton Utz as Australian legal adviser, Toronto-based Blake, Cassels & Graydon LLP as Canadian legal adviser, US-based Oppenheimer & Co Inc as financial advisor and Lonergan Edwards as an independent expert.

    About Cytopia

    Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat cancer and other diseases. Cytopia conducts its research and drug development through subsidiaries based in Australia and the USA and specialises in developing new small molecule compounds with an improved therapeutic profile for the treatment of cancer.

    The lead program for the company is CYT997, a vascular disrupting agent for the treatment of various cancers, and currently being trialled in Phase II clinical studies. Cytopia also is building on its range of JAK inhibitors
    '/>"/>

    SOURCE Cytopia Ltd.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD., AN AUSTRALIAN CANCER-FOCUSED DEVELOPMENT COMPANY
    2. Cytopia Presentation on VDA CYT997 at AACR Conference
    3. Cytopia Scientific Presentation on JAK2 Inhibitor Program at American Chemical Society Conference
    4. Cytopia Letter to Progen Shareholders
    5. Cytopia and Other Progen Shareholders Maintain Call for Meeting
    6. Presentation on Cytopias JAK2 Inhibitor Program in Myeloproliferative Disorders
    7. Cytopia Strengthens Scientific Team With US-Based Drug Development Specialist
    8. Cytopia Presentation on JAK2 Inhibitor at American Association for Cancer Research
    9. Sorrento Therapeutics, Inc. and QuikByte Software, Inc. Complete Merger
    10. Schering-Plough Shareholders Approve Merger With Merck
    11. TorreyPines Cancels Special Meeting of Stockholders in Order to Pursue Merger Transaction
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2014)... , July 30, 2014  AtheroNova Inc. (OTCBB: ... and development of compounds to safely regress atherosclerotic ... announces that its partner, CardioNova, has accomplished first ... trial with AtheroNova,s lead compound, AHRO-001.  This Phase ... AHRO-001 Phase 1 safety trial completed in February ...
    (Date:7/30/2014)... Diego, CA (PRWEB) July 30, 2014 ... announced their weighing boat special – Buy ... 1 free. This promotion will benefit lab technicians looking ... work. Weighing boats are ideal for multiple applications including ... offers a variety of choices including diamond-shaped, hexagonal, square, ...
    (Date:7/29/2014)... significant technological challenges in their quest to improve ... the James Webb Space Telescope. , The team, ... at NASA,s Goddard Space Flight Center in Greenbelt, ... that is, those activated by applying an ... current technology,s magnetically activated arrays. This advance makes ...
    (Date:7/29/2014)... HOUSTON (July 29, 2014) Tough, ultralight foam ... and shape through a chemical process invented at Rice ... "GO-0.5BN" looks like a nanoscale building, with floors and ... a pair of two-dimensional materials: floors and walls of ... boron nitride platelets. , The researchers say the ...
    Breaking Biology Technology:AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4Weighing Boat Promotion Now Available at Pipette.com, Major Pipette Distributor 2Revolutionary microshutter technology hurdles significant challenges 2Revolutionary microshutter technology hurdles significant challenges 3Revolutionary microshutter technology hurdles significant challenges 4Tough foam from tiny sheets 2
    ... FRANCISCO, Calif., Jan. 4 Cerimon,Pharmaceuticals, Inc. announced ... Counsel, a newly established position, and Vice President ... global life sciences,executive and corporate attorney with broad ... in the US and,Europe. In the business development ...
    ... efficacy in treatment of multi-drug ... resistant infections -, ... "Company"), a biopharmaceutical company focused on the,development of novel antibiotics for ... patients in two,separate Phase 2 clinical trials. The studies will evaluate ...
    ... and biotechnology ... expertise, BOSTON, Jan. 3 Observant LLC has ... for research excellence,and a commitment to client service. John ... firm as Vice President. Dr. Hartman,s,research has focused on ...
    Cached Biology Technology:Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing 2Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741 2Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741 3Observant LLC Expands Senior Management Team 2
    (Date:7/30/2014)... July 30, 2014 NexID Biometrics ... liveness detection solutions for the biometric authentication industry, ... consortium revolutionizing online authentication with standards for strong ... , "The decision to join FIDO Alliance stems ... pervasive in use. We believe the FIDO Alliance ...
    (Date:7/30/2014)... Scientists are searching through a massive collection of 20-million-year-old ... years ago, and the effort is yielding fresh insights ... , When the collection is fully curated, a task ... largest unbiased Dominican amber collection in the world, the ... thus far is that of a pygmy locust, a ...
    (Date:7/30/2014)... in cancer treatment has been shown to relieve ... for neural transmission between the peripheral and central ... Institute of Radiation Medicine, Chinese Academy of Medical ... into rat dorsal root ganglia (DRG) to provide ... radioactivity (0, 14.8, 29.6 MBq) were implanted separately ...
    Breaking Biology News(10 mins):NexID Biometrics Joins the FIDO Alliance 2Decades-old amber collection offers new views of a lost world 2
    ... 21 February 2011 Elsevier, a world-leading publisher ... services, and TAIR - The Arabidopsis Information Resource, ... elements of scientific research. All articles on Elsevier,s ... genes and use AGI codes (e.g. AT4G32520) will ...
    ... Researchers at Albert Einstein College of Medicine ... to protect against an increasingly common and particularly deadly form ... tested in an animal model, are reported in a paper ... Pneumococcal pneumonia can occur when the lungs are ...
    ... heart diseases affect approximately one in 100 patients, making ... number-one cause of pediatric deaths. Now a new ... cardiac muscle damage in a mouse model of the congenital ... treatment for this rare condition, but also demonstrates the importance ...
    Cached Biology News:Vaccine made with synthetic gene protects against deadly pneumonia 2Vaccine made with synthetic gene protects against deadly pneumonia 3Study shows rapamycin reverses myocardial defects in mouse model of LEOPARD syndrome 2Study shows rapamycin reverses myocardial defects in mouse model of LEOPARD syndrome 3
    ...
    Experion spin filters are used to filter the gel matrix and gel stain solution prior to use with the Experion automated electrophoresis system. Supplied as 10 spin filters....
    ...
    ... to PRKAR2 cAMP is a signaling ... functions. cAMP exerts its effects by activating ... the signal through phosphorylation of different target ... a tetramer composed of two regulatory and ...
    Biology Products: